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Abstract
Background Medication-induced salivary gland dysfunc-
tion (MISGD), xerostomia (sensation of oral dryness), and
subjective sialorrhea cause significant morbidity and
impair quality of life. However, no evidence-based lists of
the medications that cause these disorders exist.
Objective Our objective was to compile a list of medica-
tions affecting salivary gland function and inducing
xerostomia or subjective sialorrhea.
Data Sources Electronic databases were searched for rel-
evant articles published until June 2013. Of 3867 screened
records, 269 had an acceptable degree of relevance, quality
of methodology, and strength of evidence. We found 56
chemical substances with a higher level of evidence and 50
with a moderate level of evidence of causing the above-
mentioned disorders. At the first level of the Anatomical
Therapeutic Chemical (ATC) classification system, 9 of 14
anatomical groups were represented, mainly the alimen-
tary, cardiovascular, genitourinary, nervous, and respira-
tory systems. Management strategies include substitution
or discontinuation of medications whenever possible, oral
or systemic therapy with sialogogues, administration of
saliva substitutes, and use of electro-stimulating devices.
Limitations While xerostomia was a commonly reported
outcome, objectively measured salivary flow rate was
rarely reported. Moreover, xerostomia was mostly assessed
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as an adverse effect rather than the primary outcome of
medication use. This study may not include some medi-
cations that could cause xerostomia when administered in
conjunction with others or for which xerostomia as an
adverse reaction has not been reported in the literature or
was not detected in our search.
Conclusions We compiled a comprehensive list of medi-
cations with documented effects on salivary gland function
or symptoms that may assist practitioners in assessing
patients who complain of dry mouth while taking medi-
cations. The list may also prove useful in helping practi-
tioners anticipate adverse effects and consider alternative
medications.
Key Points
We compiled a comprehensive list of medications
with documented effects on salivary gland function
or symptoms that may assist practitioners assessing
patients who complain of dry mouth while taking
medications.
The list may also prove useful in helping
practitioners anticipate oral adverse effects and
consider alternative medications.
1 Introduction
Increased life expectancy, aging populations, and the
association of these with polypharmacy have been
intriguing topics over the last few decades. The World
Health Statistics of 2014 published on the World Health
Organization website reports a life expectancy of 55–87
years in its various constituent countries, with even the
lower economy countries reporting rapid increases in life
expectancy. However, with increased age comes a greater
number of ailments, which in turn is indicative of a higher
intake of medications.
Medications for the treatment of various diseases may
also cause adverse effects, including those related to the
oral cavity by their effects on the salivary glands. Apart
from medications used to treat salivary gland disorders,
other medications can also have the following adverse
effects: salivary gland dysfunction (SGD), including sali-
vary gland hypofunction (SGH) (an objectively measured
decrease in salivation) or objective sialorrhea (an excessive
secretion of saliva), xerostomia (subjective feeling of dry
mouth), or subjective sialorrhea (feeling of having too
much saliva). Medication-induced SGH and objective
sialorrhea are collectively termed medication-induced
salivary gland dysfunction (MISGD). The possible adverse
effects associated with these disorders, especially SGH,
include dental caries, dysgeusia, oral mucosal soreness, and
oral candidiasis.
Current literature guiding clinicians in the prescribing of
medications while considering the relevant adverse effects
on salivary glands is very scarce. Most of the available
literature attempting to list relevant drugs comprises a
compendium based on manufacturers’ drug profiles, nar-
rative reviews, and case reports, or original research papers
not containing a overall list of medications [1–10]. A
systematic evidence-based list that identifies and lists
medications that could objectively be associated with
MISGD, xerostomia, or subjective sialorrhea is lacking.
Hence, the MISGD group of the World Workshop on Oral
Medicine VI (WWOM VI) aimed to review the current
knowledge on this subject and compile a list of medications
and their objective effects on salivary gland function, based
on a high level of evidence and relevance.
2 Materials and Methods
The MISGD group comprised five reviewers (AA, RJ, NN,
YS, and AlV), six consultants (senior experts in fields
related to MISGD: DA, CD, JE, AMP, GP, and ArV), one
research librarian (RM), one group head (AW), and two
supervisors on behalf of the WWOM VI Steering Com-
mittee (SBJ and ARK). This review addresses one of the
MISGD topics covered by the group, an updated classifi-
cation of medications reported to cause objective SGD. The
research method was based on the policies and standards
set forth by a task force for WWOM IV [11] and by the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement [12], which was
adapted to the current review.
2.1 Step 1: Scope Definition
The current review covered seven research questions, as
follows:
Which medications have been reported to induce:
1. SGD in humans?
2. SGD in animals?
3. xerostomia but not SGD?
4. drooling but not SGD?
5. xerostomia-related oral symptoms (but not SGD) other
than excessive dryness/wetness?
6. xerostomia but have not been tested yet for induction
of SGD?
7. drooling but have not been tested yet for induction of
SGD?
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2.2 Step 2: Search Term Selection
The following keywords and subject headings were selec-
ted for each research question:
Q1. Medication/drugs/humans AND salivary gland dys-
function, xerostomia, dry mouth, reduced salivary
flow rate, hyposalivation, sialorrhea, drooling.
Q2. Medication/drugs/animals AND salivary gland dys-
function, reduced salivary flow rate, hyposalivation,
drooling.
Q3. Medication/drugs AND xerostomia, dry mouth,
hyposalivation AND NOT salivary dysfunction.
Q4. Medication/drugs AND drooling/sialorrhea/hyper-
salivation/ptyalism/increased salivary flow rate
AND NOT salivary dysfunction.
Q5. Medication/drugs AND salivary glands/saliva/xeros-
tomia/dry mouth/hyposalivation AND NOT salivary
gland dysfunction, oral sensory complaints.
Q6. Medication/drugs AND salivary glands/saliva/xeros-
tomia/dry mouth/hyposalivation AND NOT salivary
gland dysfunction/assessment.
Q7. Medication/drugs AND drooling/sialorrhea/hyper-
salivation/ptyalism AND NOT salivary gland dys-
function/assessment.
2.3 Step 3: Literature Search
Our literature search was conducted, through June 2013, in
the PubMed, Embase, and Web of Science databases based
on our chosen keywords and subject headings where
applicable and was not limited by publication date, publi-
cation type or language. In addition, group members were
encouraged to submit articles of interest located through
referral or hand searching. The search was completed by a
hand search of the reference lists in the eligible papers.
After duplicates were removed, 3867 records were retained
for Step 4.
2.4 Step 4: Record Screening for Eligibility
Each of the 3867 records was screened independently by
the reviewers, who were supervised by the consultants.
Papers were either retained for further analysis or excluded
because they lacked relevance to any of the research
questions; 269 papers relevant to the aforementioned topics
were retained.
2.5 Step 5: Paper Selection for Type of Study,
Relevance, and Level of Evidence
This step started with calibration among the reviewers to
ensure they applied similar standards in the performance of
their reviews. Papers were then divided among the
reviewers, who analyzed publication titles, abstracts, and
the materials and methods sections for key parameters.
2.6 Medication General Inclusion and Exclusion
Criteria
1. Particular drugs for which MISGD has been reported
were included.
2. A group of drugs or a combination of two or more drugs
without specifying the individual MISGD of each drug
under the group or combination were excluded.
3. Drugs reported to induce SGD or used in therapeutic
aspects of SGD were excluded. Thus, parasympath-
omimetics (e.g., pilocarpine and cevimeline) and the
anti-cholinesterases (e.g., physostigmine and neostig-
mine), which are used for stimulation of salivary flow in
patients experiencing a dry mouth, were not included.
4. Research drugs that were not yet marketed by the time
of writing this manuscript, or that were subsequently
removed from the market, were excluded.
Next, the retained articles were given scores based on the
following assessments:
(1) The degree of relevance: level A (study dedicated to
MISGD or xerostomia) or level B (study dedicated to
adverse effects of medications).
(2) The strength of methodology provided in the paper:
level 1 (typically meta-analyses, systematic reviews,
and randomized controlled trials [RCTs]), level 2
(typically open-label trials, observational studies,
animal studies, and epidemiological studies), or level
3 (typically narrative reviews and textbooks).
It should be noted that, in addition to the type of study
(RCT, review, etc.), the quality of study design and per-
formance were considered in assigning the level of evi-
dence. Hence, articles were assigned scores in order of
decreasing levels of evidence as follows: A1[B1[
A2[B2[A3[B3.
2.7 Step 6: In-Depth Analysis
In-depth analysis was based on expert interpretation of the
evidence. Supervised by the group head and consultants
CD and JE, reviewer RJ screened the remaining 332
selected publications by reading the full text. Another 63
papers were excluded for reasons such as assessing MISGD
and xerostomia as an outcome of minor importance, leav-
ing 269 articles for in-depth analysis. Figure 1 depicts the
steps of our work process and the distribution of the
selected publications according to their score for level of
evidence.
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As a consequence of step 6, we derived three lists of
medications:
1. 56 medications with strong evidence that were quoted
in articles with scores A1 or B1.
2. 50 medications with moderate evidence that were
quoted in articles with scores A2 or B2 but not A1 or
B1.
3. 48 medications with weak evidence that were quoted
in articles with scores not higher than A3 or B3.
3 Results
3.1 Anatomical Therapeutic Chemical (ATC)
Classification of Drugs
The World Health Organization Collaborating Centre for
Drug Statistics Methodology developed the Anatomical
Therapeutic Chemical (ATC) classification system with
defined daily doses (DDDs) as a system to classify thera-
peutic drugs. This system, which we also used, divides
drugs into five different groups according to the organ or
system on which they act and their chemical, pharmaco-
logical, and therapeutic properties. The first level contains
14 main groups according to anatomical site of action, with
therapeutic subgroups (second level). The third and fourth
levels are pharmacological and chemical subgroups,
respectively, and the fifth level is the chemical compound
itself.
We found that nine of the 14 groups in the first level
contained medications reported with a strong or moderate
level of evidence to be associated with SGD, xerostomia,
or subjective sialorrhea: alimentary tract and metabolism,
cardiovascular system, genitourinary system and sex hor-
mones, anti-infectives for systemic use, anti-neoplastic and
immunomodulating agents, musculoskeletal system, ner-
vous system, respiratory system, and sensory organs.
Among the 94 subgroups under the second level, 26 con-
tain agents were reported to be associated with SGD, with
22 having strong evidence, namely drugs for functional
gastrointestinal disorders, anti-emetics and anti-nauseants,
anti-obesity preparations, anti-hypertensives, diuretics,
beta-blocking agents, calcium channel blockers, urologi-
cals, anti-neoplastic agents, muscle relaxants, drugs for the
treatment of bone diseases, analgesics, anti-epileptics, anti-
Parkinson drugs, psycholeptics, psychoanaleptics, other
nervous system drugs, anti-muscarinic drugs for obstruc-
tive airway diseases, anti-histamines for systemic use, and
ophthalmologicals. The third level is not included in
Table 1 since it would add very little information. For the
fourth level and its 882 subgroups described in the ATC/
DDD system, 64 medication classes were found to be
associated with SGD, and in 37 of these subgroups the
association of SGD with the medications had stronger
evidence. At the fifth level, 106 substances of the 4679
specified in the system were reported with a strong or
moderate level of evidence to be associated with SGD. Of
those, 56 drugs had a higher level of evidence of associa-
tion with SGD (see Table 2).
Fig. 1 Adapted PRISMA
(Preferred Reporting Items for
Systematic Reviews and Meta-
Analyses) flowchart of the
paper-selection process
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3.2 Medications with Strong Evidence
Fifty-six medications had strong evidence of interference
with salivary gland function. These medications could be
categorized into the following eight of the ten anatomical
main groups (first level in the ATC system): alimentary
tract and metabolism (A), cardiovascular system (C),
genitourinary system and sex hormones (G), anti-neoplas-
tic and immunomodulating agents (L), musculoskeletal
system (M), nervous system (N), respiratory system (R),
and sensory organs (S). More than half (36) belong to the
ATC main category of nervous system, and the most cited
in the literature are oxybutynin (21 papers), tolterodine
(19), duloxetine (19), quetiapine (14), bupropion (12),
olanzapine (11), solifenacin (11), clozapine (9), fluoxetine
(9), and venlafaxine (8). Oxybutynin, tolterodine, and
solifenacin are urologicals, while the remainder act on the
nervous system. All medications on this list except alen-
dronate, bendroflumethiazide, and clonidine have been
reported to cause xerostomia, whereas SGH has been ver-
ified (via measurement of salivary flow rate) for alen-
dronate, amitriptyline, atropine, bendroflumethiazide,
clonidine, fluoxetine, furosemide, oxybutynin, paroxetine,
propiverine, propiverine, scopolamine, sertraline, solife-
nacin, and tolterodine. Sialorrhea was found to be an
adverse effect of clozapine, olanzapine, and venlafaxine, as
objectively assessed excess salivation, and of quetiapine
and risperidone, as a symptom. Animal experiments offer
an explanation for the dual action (oral dryness and sial-
orrhea) of clozapine [63, 120]. Dysgeusia was reported
after administration of amitriptyline, bevacizumab,
buprenorphine, fluoxetine loxapine, quetiapine, and ser-
traline; dental caries were associated with chlorpromazine
and lithium; oral candidiasis was associated with olanza-
pine; and burning mouth sensation was associated with
amitriptyline (not in Table 2). The properties of the various
drugs listed in column 3 of Tables 2 and 3 were primarily
derived from the textbook Goodman and Gilman’s The
Pharmacological Basis of Therapeutics [202].
3.3 Medications with Moderate Evidence
Fifty medications had a moderate level of evidence of
effects on salivary glands. These medications belonged to
the following seven of the ten main anatomical groups (first
level according to the ATC classification system): ali-
mentary tract and metabolism, cardiovascular system,
genitourinary system and sex hormones, anti-infectives for
systemic use, nervous system, and respiratory system.
Medications under the ATC category ‘nervous system’
were also the most commonly quoted medications in
Table 3. Xerostomia is an adverse effect of all the drugs
listed in Table 3 except clobazam, whereas SGH was
reported with darifenacin and metoprolol. Enalapril,
haloperidol, and methyldopa were reported to cause a
subjective feeling of sialorrhea. Objective sialorrhea was
reported only with clobazam. Three medications (aze-
lastine, enalapril, and fluvoxamine) were reportedly asso-
ciated with dysgeusia, and one (haloperidol) was associated
with dental caries (not in Table 3).
3.4 Medications with Weak Evidence
In total, 48 medications were reported to cause a range of
adverse oral effects, such as xerostomia, SGH, sialorrhea,
burning mouth sensation, dysgeusia, and dental caries
(Table 4).
4 Discussion
Saliva plays a crucial role in maintaining the health and
functioning of the mouth. Its functions include (1) main-
taining a moist oral mucosa, (2) mucinous content acting as
a lubricant in the mouth and oesophagus, (3) taste recog-
nition by acting as a medium for suspension of tastants, (4)
digestion of starches with the help of amylase, (5) acid
buffering in the mouth and oesophagus mainly by bicar-
bonate, (6) protection of teeth from acids by being super-
saturated with respect to tooth mineral and by contributing
to the acquired enamel pellicle, (7) modulation of the oral
microbiota with the help of anti-bacterial, anti-viral, and
anti-fungal components, and (8) facilitating wound healing
in the oral cavity [272]. Medications may act on the central
nervous system and/or at the neuroglandular junction,
explaining the pathogenesis of MISDG. The secretory cells
are supplied with muscarinic M1 and M3 receptors, a1-
and b1-adrenergic receptors, and certain peptidergic
receptors that are involved in the initiation of salivary
secretion [273]. It is therefore understandable that drugs
that have antagonistic actions on the autonomic receptors
but that are used to treat dysfunctions in the various
effectors of the autonomic nervous system may also affect
the functions of salivary glands and thus cause oral dry-
ness. However, in some cases, the cause of oral dryness is
not as evident, as with the bisphosphonate alendronate that
was reported to reduce the unstimulated secretion of saliva
[13].
The anti-muscarinic drugs are well-known inducers of
oral dryness as they prevent parasympathetic (cholinergic)
innervation from activating the secretory cells. Surpris-
ingly, clinical studies directly focusing on the secretion of
saliva and the flagship of the anti-muscarinics, atropine,
seem few. This is in contrast to numerous studies on ani-
mals, starting with the observations of the pioneers of
salivary physiology in the 1870s.
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Table 1 Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with higher and moderate level of evidence,
grouped according to their inclusion in first, second, fourth, and fifth ACT levels
First level, anatomical main
group
Second level, therapeutic
subgroup
Fourth level, chemical subgroup Fifth level, chemical
substance
ATC code
Alimentary tract and
metabolism
Drug for functional GI
disorder
Synthetic anti-cholinergics, quaternary
ammonium compounds
Propantheline A03AB05
Belladonna alkaloids, tertiary amines Atropine A03BA01
Hyoscyamine A03BA03
Belladonna alkaloids, semisynthetic,
quaternary ammonium compounds
Scopolamine/
hyoscine
A03BB01
Anti-emetics and anti-
nauseants
Other anti-emetics Scopolamine/
hyoscine
A04AD01
Anti-obesity preparations,
excl. diet products
Centrally acting anti-obesity products Phentermine A08AA01
Dexfenfluramine A08AA04
Sibutramine A08AA10
Peripherally acting anti-obesity products Orlistat A08AB01
Serotonin–noradrenaline–dopamine
reuptake inhibitor
Tesofensine ND
Cardiovascular system Cardiac therapy Anti-arrhythmics, class Ib Mexiletine C01BB02
Anti-hypertensives Methyldopa Methyldopa C02AB01
Imidazoline receptor agonists Clonidine C02AC01
Diuretics Thiazides, plain Bendroflumethiazide C03AA01
Sulfonamides, plain Furosemide C03CA01
Vasopressin antagonists Tolvaptan C03XA01
Beta-blocking agents Beta-blocking agents, non-selective Timolol C07AA06
Beta-blocking agents, selective Metoprolol C07AB02
Atenolol C07AB03
Calcium channel blockers Dihydropyridine derivatives Isradipine C08CA03
Phenylalkylamine derivatives Verapamil C08DA01
Agents acting on the renin-
angiotensin system
ACE inhibitors, plain Enalapril C09AA02
Lisinopril C09AA03
Genitourinary system and
sex hormones
Urologicals Drugs for urinary frequency and
incontinence
Oxybutynin G04BD04
Propiverine G04BD06
Tolterodine G04BD07
Solifenacin G04BD08
Trospium G04BD09
Darifenacin G04BD10
Fesoterodine G04BD11
Imidafenacin ND
Alpha-adrenoreceptor antagonists Alfuzosin G04CA01
Terazosin G04CA03
Anti-infectives for systemic
use
Anti-virals for systemic use Protease inhibitors Saquinavir J05AE01
Nucleoside and nucleotide reverse
transcriptase inhibitors
Didanosine J05AF02
Lamivudine J05AF05
Non-nucleoside reverse transcriptase
inhibitors
Nevirapine J05AG01
Etravirine J05AG04
Other anti-virals Raltegravir J05AX08
Maraviroc J05AX09
Anti-neoplastic and
immunomodulating
agents
Anti-neoplastic agents Monoclonal antibodies Bevacizumab L01XC07
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Table 1 continued
First level, anatomical main
group
Second level, therapeutic
subgroup
Fourth level, chemical subgroup Fifth level, chemical
substance
ATC code
Musculoskeletal system Muscle relaxants Other centrally acting agents Baclofen M03BX01
Tizanidine M03BX02
Cyclobenzaprine M03BX08
Drugs for treatment of
bone diseases
Bisphosphonates Alendronate M05BA04
Nervous system Anesthetics Opioid anesthetics Fentanyl N01AH01
Analgesics Natural opium alkaloids Morphine N02AA01
Dihydrocodeine N02AA08
Phenylpiperidine derivatives Fentanyl N02AB03
Oripavine derivatives Buprenorphine N02AE01
Morphinan derivatives Butorphanol N02AF01
Other opioids Tramadol N02AX02
Tapentadol N02AX06
Other anti-migraine preparations Clonidine N02CX02
Anti-epileptics Fatty acid derivatives Sodium
valproate/valproic
acid
N03AG01
Other anti-epileptics Gabapentin N03AX12
Pregabalin N03AX16
Anti-Parkinson drugs Dopamine agonists Rotigotine N04BC09
Psycholeptics Phenothiazines with aliphatic side-chain Chlorpromazine N05AA01
Phenothiazines with piperazine structure Perphenazine N05AB03
Butyrophenone derivatives Haloperidol N05AD01
Indole derivatives Sertindole N05AE03
Ziprasidone N05AE04
Lurasidone N05AE05
Diazepines, oxazepines, thiazepines, and
oxepines
Loxapine N05AH01
Clozapine N05AH02
Olanzapine N05AH03
Quetiapine N05AH04
Asenapine N05AH05
Benzamides Amisulpride N05AL05
Lithium Lithium N05AN01
Other anti-psychotics Risperidone N05AX08
Aripiprazole N05AX12
Paliperidone N05AX13
Benzodiazepine derivatives (anxiolytics) Clobazam N05BA09
Benzodiazepine-related drugs Zolpidem N05CF02
Eszopiclone N05CF04
Zopiclone N05CF01
Other hypnotics and sedatives Scopolamine/
hyoscine
N05CM05
Dexmedetomidine N05CM18
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The number of patients adversely affected by a specific
drug, as well as the severity of the effect of this drug, are
usually dose dependent. Figures for these parameters are
not presented in the current study. Lack of saliva is often
manifested as the sensation of dry mouth (xerostomia). A
number of studies have suggested an association between
the incidence of xerostomia and the number and dose of
medications [274]. That study also discussed secondary
effects of MISGD in promoting caries or oral mucosal
alterations.
Management of MISGD has mainly been based on a
trial-and-error approach. Use of intraoral topical agents,
such as a spray containing malic acid, sugar-free chewing
gums or candy, saliva substitutes, or non-alcoholic
mouthwashes to moisten or lubricate the mouth have
served as the mainstay of treatment for patients with a dry
Table 1 continued
First level, anatomical main
group
Second level, therapeutic
subgroup
Fourth level, chemical subgroup Fifth level, chemical
substance
ATC code
Psychoanaleptics Non-selective monoamine reuptake
inhibitors
Desipramine N06AA01
Imipramine N06AA02
Amitriptyline N06AA09
Nortriptyline N06AA10
Doxepin N06AA12
Dosulepin N06AA16
Selective serotonin reuptake inhibitors Fluoxetine N06AB03
Citalopram N06AB04
Paroxetine N06AB05
Sertraline N06AB06
Escitalopram N06AB10
Other anti-depressants Bupropion N06AX12
Venlafaxine N06AX16
Reboxetine N06AX18
Duloxetine N06AX21
Desvenlafaxine N06AX23
Vortioxetine N06AX26
Centrally acting sympathomimetics Methylphenidate N06BA04
Dexmethylphenidate N06BA11
Lisdexamfetamine N06BA12
Other nervous system
drugs
Drugs used in nicotine dependence Nicotine N07BA01
Drugs used in alcohol dependence Naltrexone N07BB04
Drugs used in opioid dependence Buprenorphine N07BC01
ND ND Dimebon ND
Tesofensine ND
Respiratory system Nasal preparations Anti-allergic agents, excl. corticosteroids Azelastine R01AC03
Drugs for obstructive
airway diseases
Anti-cholinergics Tiotropium R03BB04
Anti-histamines for
systemic use
Aminoalkyl ethers Doxylamine R06AA09
Piperazine derivatives Cetirizine R06AE07
Levocetirizine R06AE09
Other anti-histamines for systemic use Ebastine R06AX22
Desloratadine R06AX27
Sensory organs Ophthalmologicals Sympathomimetics in glaucoma therapy Brimonidine S01EA05
Anti-cholinergics Atropine S01FA01
Other anti-allergics Azelastine S01GX07
ACE angiotensin-converting enzyme, ATC Anatomical Therapeutic Chemical, GI gastrointestinal, ND not determined
a Bold type indicates higher level of evidence
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mouth. Parasympathomimetic agents with potent mus-
carinic-stimulating properties, such as pilocarpine and
cevimeline, and anti-cholinesterases, which reduce the rate
of acetylcholine metabolism, have been used as systemic
sialogogues. Although they increase salivation signifi-
cantly, the adverse effect profile of these drugs upon sys-
temic administration restricts their use in patients with
MISGD. A local application of these categories of drugs
onto the oral epithelium, with the aim of activating the
underlying minor glands, may be an alternative approach.
It is also necessary to ensure salivary gland functionality
before administering these medications. Newer manage-
ment methods include electrostimulation. Other manage-
ment options for MISGD include possibly reducing the
number of medications or the dosage or replacing them
with medications or formulations with fewer xerogenic
effects. Little evidence is available on this important topic;
however, when dental treatment is needed, close commu-
nication between the dentist (who has to deal with the
adverse effects) and the prescribing physician is warranted
to obtain the best outcome for the patient [275].
The present paper tries to fill the lacunae in regard to
evidence-based listing of the effects of medications on
salivary function as found in the current scientific litera-
ture. We conducted an extensive search of the literature
related to MISGD, followed by meticulous scrutiny and
analysis of the articles. However, it is still possible that a
few medications were missed, and the lists in Tables 2 and
3 may not be exhaustive. Grading the evidence and rele-
vance of each scientific article was a major issue. Conse-
quently, the number of medications with strong or
moderate evidence of being associated with SGD and
xerostomia in our lists is much smaller than in other lists
[1–6, 9]. Moreover, some studies may have recorded
salivary disorders only in an adverse effect table, and these
would have been missed by our search. An additional issue
is that our study does not include preparations containing
more than one agent. However, any medication included in
a mixed medication in these lists may have the potential to
influence the salivary effects of the overall preparation. A
further matter that warrants consideration is the possibility
that certain drugs, while not exerting xerogenic effect
when taken individually (and therefore not appearing in
these lists), may do so as a result of drug–drug interaction
if consumed together in a polypharmacy context [7, 8]. It
should also be noted that, for some medications not
included in this review because peer-reviewed publications
on their salivary side effects were lacking, such side effects
could have been mentioned on their monographs according
to their manufacturer’s controlled clinical trial. Finally,
this article does not report the potency and frequency of
salivary effects of the medications, as these data were
rarely available.T
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The study suggests that medications acting on almost all
systems of the body may also cause side effects related to
the salivary system. At higher levels of the classification
tree, the analysis seems to yield more specific details of the
medications and their modes of action leading to SGD and
xerostomia. Hence, the selection of an alternate drug with a
similar effect on the desired system but fewer adverse
salivary effects may be attempted based on this list.
However, the possibility exists that other drugs that belong
to the same level, especially at the fourth level of the ATC/
DDD classification, may have a similar effect on salivary
glands as the drug to be replaced.
Very few studies used objective measurements of sali-
vary flow rates in the context of a medication adverse
effect [7, 8, 13, 48]. Further, few articles seem to have
correlated the results of such objective measurements with
the subjective feelings of the patients receiving these
drugs. Though animal studies have established a reduced
salivary flow rate as an effect of medications, the subjec-
tive feeling of dryness (xerostomia) obviously cannot be
registered in animals; hence, the relationship between
changes in salivary flow rate and subjective feelings of
dryness/drooling has been ambiguous
[104, 120, 138–140, 148].
It has been reported that xerostomia in healthy subjects
is not experienced until the unstimulated flow rate of whole
saliva has been reduced to 40–50% of normal [27]. Fur-
thermore, whether changes in the composition of the sali-
vary secretion can also affect the subjective feelings of the
patient remains to be clarified. However, the main diffi-
culty encountered was the rarity of studies in which sali-
vary flow rate or composition was actually measured
before and after patients were prescribed medication.
Moreover, baseline data were available for virtually no
patients regarding their unstimulated saliva flow rates
before they require medications. It seems to be only in
Sweden that dental students are taught to measure the
salivary flow rates of their patients to provide baseline
values for any subsequent salivary problems that may
develop. We suggest this is a valuable approach that should
also be introduced in other countries.
Medications were also reported to cause other oral
adverse effects. Aliko et al. [274] point out that although
independent reports relate a burning sensation of the oral
mucosa and/or dysgeusia with MISGD, the relationship has
not been established objectively. A few articles (albeit of
moderate or weak level of evidence) mention that can-
didiasis and dental caries are associated with the use of
certain drugs. None of these studies has tested the rela-
tionship between the pharmacokinetics of the drug, its
effect on salivary glands, and other oral adverse effects
reported [274]. Dawes et al. [272] reported that con-
stituents of saliva have anti-fungal, anti-viral, and anti-T
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Table 4 Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with weaker level of evidence
Drug name Number of citations for: Sources per level of evidence (n) Total publications (n) References
Oral ‘dryness’ Sialorrhea
Xerostomia SGH Subjective Objective A3 B3
Amiloride 0 1 0 0 1 0 1 [14]
Apraclonidine 1 0 0 0 0 1 1 [26]
Asimadoline 1 0 0 0 0 1 1 [252]
Atomoxetine 1 0 0 0 0 1 1 [253]
Biperiden 1 1 0 0 1 0 1 [14]
Chlorpheniramine 1 0 0 0 0 1 1 [254]
Chlorprothixene 0 1 0 0 1 0 1 [14]
Cisplatin 1 0 0 0 0 1 1 [255]
Clomipramine 3 0 0 0 0 3 3 [90, 95, 145]
Cyclothiazide 0 1 0 0 1 0 1 [14]
Cytisine 1 0 0 0 0 1 1 [256]
Diltiazem 0 1 0 0 1 0 1 [14]
Dimenhydrinate 2 0 0 0 0 2 2 [167, 254]
Diphenhydramine 1 0 0 0 0 1 1 [254]
Disopyramide 1 0 0 0 1 0 1 [14]
Flupirtine 1 0 0 0 0 1 1 [257]
Granisetron 1 0 0 0 0 1 1 [258]
Guanfacine 2 0 0 0 0 2 2 [53, 259]
Interleukin-2a 0 1 0 0 1 0 1 [14]
Ipratropium 1 0 0 0 0 1 1 [260]
Levomepromazine 0 1 0 0 1 0 1 [14]
Maprotiline 1 1 0 0 1 0 1 [14]
Mazindol 1 0 0 0 0 1 1 [100]
Melperone 0 1 0 0 1 0 1 [14]
Mepyramine 1 0 0 0 0 1 1 [254]
Metiamide 0 1 0 0 1 0 1 [14]
Milnacipran 3 0 0 0 0 3 3 [85, 261, 262]
Mirtazapine 2 0 0 0 0 2 2 [18, 263]
Moclobemide 1 0 0 0 0 1 1 [112]
Modafinil 2 0 0 0 0 2 2 [90, 264]
Mosapride 1 0 0 0 0 1 1 [265]
Moxifloxacin 1 0 0 0 0 1 1 [266]
Moxonidine 3 0 0 0 0 3 3 [50, 53, 267]
Nefazodone 2 0 0 0 0 2 2 [268, 269]
Oxitropium 1 0 0 0 0 1 1 [260]
Perindopril 1 0 0 0 0 1 1 [270]
Pethidine 0 1 0 0 1 0 1 [14]
Phenelzine 1 0 0 0 0 1 1 [113]
Pheniramine 0 1 0 0 0 1 1 [254]
Promazine 1 0 0 0 0 1 1 [157]
Protriptyline 2 0 0 0 0 2 2 [90, 100]
Pseudoephedrine 1 0 0 0 0 1 1 [207]
Rilmenidine 2 0 0 0 0 2 2 [53, 266]
Selegiline 1 1 0 0 1 1 2 [14, 112]
Thioridazine 2 1 0 0 1 0 1 [14]
Tianeptine 1 0 0 0 1 0 1 [271]
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bacterial properties, which indicates the role of saliva in
controlling the oral microbiota and correlates SGH with
occurrence of oral candidiasis. The relationship between
SGH, dental caries, and oral candidiasis is well known and
established. However, the same has not been tested in the
context of MISGD in the current literature.
The present paper may help clinicians and researchers
consider whether the medications they prescribe or inves-
tigate may lead to SGD or xerostomia. A few scenarios
follow:
(a) A clinician needs to evaluate which drugs from the
medication list of his/her patient have potential
adverse salivary effects. The clinician may take the
following steps:
(i) Search in Tables 2 and 3 for the medications by
alphabetical order.
(ii) If the medications are not found, there is
probably no published evidence for a salivary
adverse effect.
(iii) If found and they wish to know more about the
medication type, they can search Table 1 using
the ATC code(s) found in column 2 of Tables 2
and 3. These codes are in the last column of
Table 1 in alphabetical and numerical order.
(b) Before prescribing a medication, a clinician wishes to
assess its potential salivary adverse effects. The above
decision tree is also recommended in this situation.
(c) A treated patient complains of salivary symptoms but
the clinician cannot find any of the medications in
Tables 2 or Table 3. However, it is plausible that
additional medications not included in these
tables could also affect salivary glands if they belong
to the same ATC category at any level. For example,
the anti-obesity medications fenfluramine, amfepra-
mone, mazindol, etilamfetamine, cathine, cloben-
zorex, mefenorex, and lorcaserin are all ‘centrally
acting anti-obesity products’, ATC A08AA [276], and
may act similarly to dexfenfluramine, which belongs
to the same category and appears in Table 3. Such an
association may provide an explanation for the
patient’s symptoms.
(d) A clinician needs to prescribe medication to a patient
with Sjo¨gren’s syndrome or who has undergone
radiotherapy to the head and neck area and wishes
to avoid worsening the patient’s xerostomia. If, for
example, the required drug is a muscle relaxant, the
clinician may search the ATC website [277] under
‘muscle relaxants’ and then double check the sub-
groups and Table 1. There, they will find that ‘other
centrally acting agents’ may have salivary effects and
thus choose a medication belonging to any of the
other subgroups.
(e) A researcher wishes to know whether a certain type of
medication has salivary effects and at what level of
evidence.
(i) The researcher may start searching Table 1 for
the type of medication according to the anatom-
ical site of action (first level), therapeutic effect
(second level), chemical characteristic (fourth
level), or generic name (fifth level).
(ii) If no relevant category is found, there is
probably no published evidence for adverse
salivary effects of this drug type.
(iii) If the drug type is found at any of the levels in
bold text, one of the drugs at the fifth level
belonging to the category may be searched for
in Table 2, where the medications are in
alphabetical order and information is available,
i.e., type and number of publications and
references.
(iv) If the drug type is found but not in bold text, the
researcher may proceed as in (iii) above but in
Table 3 instead of Table 2.
5 Conclusions
Most investigators relied on the subjective opinion of the
individuals or patients about whether they had too little or
an excessive secretion of saliva. Thus, we conclude that
further RCTs that include saliva collection are warranted
for the assessment of potential salivary effects of many
Table 4 continued
Drug name Number of citations for: Sources per level of evidence (n) Total publications (n) References
Oral ‘dryness’ Sialorrhea
Xerostomia SGH Subjective Objective A3 B3
Triprolidine 1 0 0 0 0 1 1 [254]
Zimelidine 0 1 0 0 1 0 1 [14]
SGH salivary gland hypofunction
20 A. Wolff et al.
medications. Unstimulated and stimulated salivary flow
rates should be measured before and at intervals after
starting the drug. In addition, a record of changes in the
patients’ subjective feelings over time should also be kept.
Ideally, studies should also aim to assess changes in sali-
vary composition, since these may also relate to SGD.
Acknowledgements The authors, including selected members of the
WWOM VI Steering Committee, express their sincere appreciation
for the opportunity to collaborate with the full WWOM VI Steering
Committee over these past 3 years. This committee provided the
conceptual framework and logistical support to produce the WWOM
VI Conference in April 2014 in Orlando, Florida, USA. In addition,
the Steering Committee provided scientific and editorial critiques of
this manuscript. The entire Steering Committee is listed below, in
alphabetical order: Martin S. Greenberg (USA), Timothy A. Hodgson
(UK), Siri Beier Jensen (Denmark), A. Ross Kerr (USA), Peter B.
Lockhart (USA), Giovanni Lodi (Italy), Douglas E. Peterson (USA),
and David Wray (UK and Dubai).
Compliance with Ethical Standards
Funding The authors gratefully acknowledge the following organi-
zations, individuals, and companies that provided unrestricted finan-
cial support for WWOM VI: American Academy of Oral Medicine,
European Association of Oral Medicine, anonymous gifts from
patients of Dr. David Sirois, New York University, College of Den-
tistry, Biocosmetics, Elsevier, Johnson and Johnson, The Oral Cancer
Foundation, and Unilever.
Conflict of interest AW owns stocks in Saliwell Ltd., a company
that deals with electrostimulation devices to treat xerostomia. RKJ,
JE, DA, AMLP, GP, NN, A Villa, YWS, AA, RM, ARK, SBJ, A
Vissink, and CD have no conflicts of interest that are directly related
to the content of this article.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Smith RG, Burtner AP. Oral side-effects of the most frequently
prescribed drugs. Spec Care Dentist. 1994;14:96–102.
2. Sreebny LM, Schwartz SS. A reference guide to drugs and dry
mouth. Gerodontology. 1997;14:33–7.
3. Sreebny LM. The causes of dry mouth: a broad panoply. In:
Sreebny LM, Vissink A, editors. Dry mouth, the malevolent
symptom: a clinical guide. Ames: Wiley-Blackwell; 2010.
p. 103–22.
4. Wolff A, Stahl B. Reference guide to xerogenic drugs in Israel.
J Isr Dent Assoc. 1999;16:51–76.
5. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis.
2003;9:165–76.
6. Scully C, Bagan-Sebastian JV. Adverse drug reactions in the
orofacial region. Crit Rev Oral Biol Med. 2004;15:221–40.
7. Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM.
Associations between oral and ocular dryness, labial and whole
salivary flow rates, systemic diseases and medications in a
sample of older people. Community Dent Oral Epidemiol.
2011;39:276–88.
8. Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM.
Associations between labial and whole salivary flow rates,
systemic diseases and medications in a sample of older people.
Community Dent Oral Epidemiol. 2010;38:422–35.
9. Nguyen CT, MacEntee MI, Mintzes B, Perry TL. Information
for physicians and pharmacists about drugs that might cause dry
mouth: a study of monographs and published literature. Drugs
Aging. 2014;31:55–65.
10. Lynge Pedersen AM, Nauntofte B, Smidt D, Torpet LA. Oral
mucosal lesions in older people: relation to salivary secretion,
systemic diseases and medications. Oral Dis. 2015;21:721–9.
11. Baccaglini I, Brennan MT, Lockhart PB, Patton LL. World
Workshop on Oral Medicine IV. Process and methodology for
systematic review and developing management recommenda-
tions. Reference manual for management recommendations
writing committees. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2007;103(Suppl S3);e1–19.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group.
Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. Ann Intern Med.
2009;151:264–9.
13. Evio¨ S, Tarkkila L, Sorsa T, Furuholm J, Va¨lima¨ki MJ, Yliko-
rkala O, et al. Effects of alendronate and hormone replacement
therapy, alone and in combination, on saliva, periodontal con-
ditions and gingival crevicular fluid matrix metalloproteinase-8
levels in women with osteoporosis. Oral Dis. 2006;12:187–93.
14. Narhi TO, Meurman JH, Ainamo A. Xerostomia and hyposali-
vation: causes, consequences and treatment in the elderly. Drugs
Aging. 1999;15:103–16.
15. Pawar PS, Woo DA. Extrapyramidal symptoms with concomi-
tant use of amitriptyline and amiodarone in an elderly patient.
Am J Geriatr Pharmacother. 2010;8:595–8.
16. Rani PU, Naidu MU, Prasad VB, Rao TR, Shobha JC. An
evaluation of antidepressants in rheumatic pain conditions.
Anesth Analg. 1996;83:371–5.
17. Sauer H, Huppertz-Helmhold S, Dierkes W. Efficacy and safety
of venlafaxine ER vs. amitriptyline ER in patients with major
depression of moderate severity. Pharmacopsychiatry.
2003;36:169–75.
18. Montgomery SA. Safety of mirtazapine: a review. Int Clin
Psychopharmacol. 1995;10(Suppl 4):37–45.
19. Nagata E. Antidepressants in migraine prophylaxis. Brain
Nerve. 2009;61:1131–4.
20. Jain T, Bhandari A, Ram V, et al. Drug interactions and adverse
drug reactions in hospitalized psychiatric patients: a critical
element in providing safe medication use. German J Psychiatry.
2011;14:26–34.
21. Biederman J, Mick E, Spencer T, Doyle R, Hoshi G, Ham-
merness R, et al. An open-label trial of aripiprazole monother-
apy in children and adolescents with bipolar disorder. CNS
Spectr. 2007;12:683–9.
22. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in
the treatment of bipolar disorder: a systematic review. Ann Gen
Psychiatry. 2009;8:16–30.
23. Tramontina S, Zeni CP, Pheula GF, Pheula GF, Narvaez J,
Rohde LA. Aripiprazole in juvenile bipolar disorder comorbid
with attention-deficit/hyperactivity disorder: an open clinical
trial. CNS Spectr. 2007;2:758–62.
24. Veselinovic T, Schorn H, Vernaleken I, Hiemke C, Zernig G,
Gur R, et al. Effects of antipsychotic treatment on psy-
chopathology and motor symptoms. A placebo-controlled study
in healthy volunteers. Psychopharmacol. 2011;218:733–48.
Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia and Subjective Sialorrhea 21
25. Hewer RD, Jones PM, Thomas PS, McKenzie DK. A prospec-
tive study of atropine premedication in flexible bronchoscopy.
Aust N Z J Med. 2000;30:466–9.
26. Diamond JP. Systemic adverse effects of topical ophthalmic
agents. Implications for older patients. Drugs Aging.
1997;11:352–60.
27. Dawes C. Physiological factors affecting salivary flow rate, oral
sugar clearance, and the sensation of dry mouth in man. J Dent
Res. 1987;66(Spec Iss):648–53.
28. Chou R, Peterson K, Helfand M. Comparative efficacy and
safety of skeletal muscle relaxants for spasticity and muscu-
loskeletal conditions: a systematic review. J Pain Symptom
Manag. 2004;28:140–75.
29. Nederfors T, Nauntofte B, Twetman S. Effects of furosemide
and bendroflumethiazide on saliva flow rate and composition.
Arch Oral Biol. 2004;49:507–13.
30. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy
and safety of bevacizumab for the treatment of advanced hep-
atocellular carcinoma: a systematic review of phase II trials.
PLoS One. 2012;7:e49717.
31. Walters TR. Development and use of brimonidine in treating
acute and chronic elevations of intraocular pressure: a review of
safety, efficacy, dose response, and dosing studies. Surv Oph-
thalmol. 1996;41(Suppl 1):S19–26.
32. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D,
Chen K. A, 1-year study of brimonidine twice daily in glaucoma
and ocular hypertension. A controlled, randomized, multicenter
clinical trial. Chronic Brimonidine Study Group. Arch Oph-
thalmol. 1997;115:847–52.
33. Gordon A, Callaghan D, Spink D, Cloutier C, Dzongowski P,
O’Mahoney W. Buprenorphine transdermal system in adults
with chronic low back pain: a randomized, double-blind, pla-
cebo-controlled crossover study, followed by an open-label
extension phase. Clin Ther. 2010;32:844–60.
34. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A,
McGuire H, et al. Escitalopram versus other antidepressive
agents for depression. Cochrane Database Syst Rev. 2009;(2):
CD006532.
35. Graham J, Coghill D. Adverse drug reactions in hospital in-
patients: a pilot study. CNS Drugs. 2008;22:213–37.
36. Hewett K, Chrzanowski W, Schmitz M, Milanova V, Gee M,
Krishen A, et al. Eight-week, placebo-controlled, double-blind
comparison of the antidepressant efficacy and tolerability of
bupropion XR and venlafaxine XR. J Psychopharmacol.
2009;23:531–8.
37. Jafarinia M, Mohammadi MR, Modabbernia A, Ashrafi M,
Khajavi D, Tabrizi M, et al. Bupropion versus methylphenidate
in the treatment of children with attention-deficit/hyperactivity
disorder: randomized double-blind study. Hum Psychopharma-
col. 2012;27:411–8.
38. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Gut-
tadauria M, Erickson J. Effect of naltrexone plus bupropion on
weight loss in overweight and obese adults (COR-I): a multi-
centre, randomised, double-blind, placebo-controlled, phase 3
trial. Lancet. 2010;376:595–605.
39. James WA, Lippmann S. Bupropion: overview and prescribing
guidelines in depression. S Med J. 1991;84:222–4.
40. Semenchuk MR, Sherman S, Davis B. Double-blind, random-
ized trial of bupropion SR for the treatment of neuropathic pain.
Neurol. 2001;57:1583–8.
41. Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM,
Ascher JA. Bupropion sustained release versus paroxetine for
the treatment of depression in the elderly. J Clin Psychiatry.
2000;61:196–202.
42. Zwar N, Richmond R. Bupropion sustained release. A thera-
peutic review of Zyban. Aust Fam Physician. 2002;31:443–7.
43. Andrews JM, Nemeroff CB. Contemporary management of
depression. Am J Med. 1994;97:(6A)24S–32S.
44. Muller F, Wehbe L. Smoking and smoking cessation in Latin
America: a review of the current situation and available treat-
ments. Int J COPD. 2008;3:285–93.
45. Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues
S, et al. Incremental efficacy of adding bupropion to the nicotine
patch for smoking cessation in smokers with a recent history of
alcohol dependence: results from a randomized, double-blind,
placebo-controlled study. Drug Alcohol Depend.
2011;118:111–8.
46. Wang F, Shen X, Liu Y, Xu S, Guo X. Continuous infusion of
butorphanol combined with intravenous morphine patient-con-
trolled analgesia after total abdominal hysterectomy: a ran-
domized, double-blind controlled trial. Eur J Anaesthesiol.
2009;26:28–34.
47. Adams CE, Rathbone J, Thornley B, Clarke M, Borrill J,
Wahlbeck K, et al. Chlorpromazine for schizophrenia: a
Cochrane systematic review of 50 years of randomised con-
trolled trials. BMC Med. 2005;3:15.
48. de Almeida Pdel V, Gregio AM, Brancher JA, de Lima AA,
Azevedo LR. Effects of antidepressants and benzodiazepines on
stimulated salivary flow rate and biochemistry composition of
the saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2008;106:58–65.
49. Hellerstein DJ, Batchelder S, Miozzo R, Kreditor D, Hyler S,
Gangure D. Citalopram in the treatment of dysthymic disorder.
Int Clin Psychopharmacol. 2004;19:143–8.
50. Webster J, Koch HF. Aspects of tolerability of centrally acting
antihypertensive drugs. J Cardiovasc Pharmacol. 1996;27(Suppl
3):S49–54.
51. Geyer O, Schmidt KG, Pianka P, Neudorfer M, Lazar M.
Clonidine provides an allergy-free alternative in glaucoma
patients with proven allergy to apraclonidine. Graefes Arch Clin
Exp Ophthalmol. 2000;238:149–52.
52. Villaseca P. Non-estrogen conventional and phytochemical
treatments for vasomotor symptoms: what needs to be known for
practice? Climacteric. 2012;15:115–24.
53. van Zwieten PA. Centrally acting antihypertensives: a renais-
sance of interest. Mechanisms and haemodynamics. J Hypertens
Suppl. 1997;15:S3–8.
54. Pla¨nitz V. Crossover comparison of moxonidine and clonidine
in mild to moderate hypertension. Eur J Clin Pharmacol.
1984;27:147–52.
55. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus
typical neuroleptic medication for schizophrenia. Cochrane
Database Syst Rev. 2009;(1):CD000059.
56. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-
blind comparison of olanzapine versus clozapine in schizo-
phrenic patients clinically eligible for treatment with clozapine.
Biol Psychiatry. 2001;49:52–63.
57. Ekstro¨m J, Godoy T, Riva A. Clozapine: agonistic and antago-
nistic salivary secretory actions. J Dent Res. 2010;89:276–80.
58. Soler Roibal MA, Oca Bravo L, Montejo Iglesias LM. The
clozapine-induced hypersalivation and its treatment. Actas Esp
Psiquiatr. 1999;27:408–11.
59. Immadisetty V, Agrawal P. A successful treatment strategy for
clozapine-induced parotid swelling: a clinical case and system-
atic review. Therap Adv Psychopharmacol. 2012;2:235–9.
60. Bennett JP Jr, Landow ER, Schuh LA. Suppression of dyski-
nesias in advanced Parkinson’s disease. II. Increasing daily
clozapine doses suppress dyskinesias and improve Parkinsonism
symptoms. Neurology. 1993;43:1551–5.
61. Ekstro¨m J, Khosravani N, Castagnola M, Messana I. Saliva and
the control of its secretion. In: Ekberg O, editor. Dysphagia:
22 A. Wolff et al.
diagnosis and treatment. Berlin: Springer-Verlag; 2012.
p. 19–47.
62. Godoy T, Riva A, Ekstro¨m J. Clozapine-induced salivation:
interaction with N-desmethylclozapine and amisulpride in an
experimental rat model. Eur J Oral Sci. 2011;119:275–81.
63. Praharaj SK, Jana AK, Goswami K, Das PR, Goyal N, Sinha
VK. Salivary flow rate in patients with schizophrenia on
clozapine. Oral Dis. 2012;18:680–91.
64. Darwish M, Hellriegel ET. Steady-state pharmacokinetics of
once-daily cyclobenzaprine extended release: a randomized,
double-blind, 2-period crossover study in healthy volunteers.
Clin Ther. 2011;33:746–53.
65. Moldofsky H, Harris HW, Archambault WT, Kwong T, Led-
erman S. Effects of bedtime very low dose cyclobenzaprine on
symptoms and sleep physiology in patients with fibromyalgia
syndrome: a double-blind randomized placebo-controlled study.
J Rheumatol. 2011;38:2653–63.
66. Weil AJ, Ruoff GE, Nalamachu S, Altman CA, Xie F, Taylor
DR. Efficacy and tolerability of cyclobenzaprine extended
release for acute muscle spasm: a pooled analysis. Postgrad
Med. 2010;122:158–69.
67. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z,
et al. Efficacy of dexmethylphenidate for the treatment of fati-
gue after cancer chemotherapy: a randomized clinical trial.
J Pain Symptom Manage. 2009;38:650–62.
68. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS,
Bachurin SO, et al. Effect of dimebon on cognition, activities of
daily living, behaviour, and global function in patients with
mild-to-moderate Alzheimer’s disease: a randomised, double-
blind, placebo-controlled study. Lancet. 2008;372:207–15.
69. Koren G, Clark S, Hankins GDV, Caritis SN, Miodovnik M,
Umans JG, et al. Effectiveness of delayed-release doxylamine
and pyridoxine for nausea and vomiting of pregnancy: a ran-
domized placebo controlled trial. Am J Obstet Gynecol.
2010;203:571.e571–571.e577.
70. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Rad-
cliffe M, Viktrup L. A retrospective pooled analysis of dulox-
etine safety in 23,983 subjects. Curr Med Res Opin.
2007;23:175–84.
71. Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich
MM. Flexible dosed duloxetine in the treatment of fibromyalgia:
a randomized, double-blind, placebo-controlled trial.
J Rheumatol. 2010;37:2578–86.
72. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of
duloxetine 30 mg/d in patients with fibromyalgia: a randomized,
double-blind, placebo-controlled study. Clin J Pain.
2012;28:775–81.
73. Carter NJ, McCormack PL. Duloxetine: a review of its use in the
treatment of generalized anxiety disorder. CNS Drugs.
2009;23:523–41.
74. Frampton JE, Plosker GL. Duloxetine: a review of its use in the
treatment of major depressive disorder. CNS Drugs.
2007;21:581–609.
75. Katona C, Hansen T, Olsen CK. A randomized, double-blind,
placebo-controlled, duloxetine-referenced, fixed-dose study
comparing the efficacy and safety of Lu AA21004 in elderly
patients with major depressive disorder. Int Clin Psychophar-
macol. 2012;27:215–23.
76. Norman TR, Olver JS. Duloxetine in the treatment of general-
ized anxiety disorder. Neuropsychiatric Dis Treat.
2008;4:1169–80.
77. Ormseth MJ, Scholz BA, Boomershine CS. Duloxetine in the
management of diabetic peripheral neuropathic pain. Patient
Prefer Adherence. 2011;5:343–56.
78. Perahia DGS, Kajdasz DK, Royer MG, Raskin J, Tylee A.
Duloxetine in the treatment of major depressive disorder: an
assessment of the relationship between outcomes and episode
characteristics. Int Clin Psychopharmacol. 2006;21:285–95.
79. Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG,
Kornstein SG. Duloxetine in the treatment of major depressive
disorder: comparisons of safety and tolerability in male and
female patients. J Affect Disord. 2006;94:183–9.
80. Wright A, VanDenBerg C. Duloxetine in the treatment of gen-
eralized anxiety disorder. Int J Gen Med. 2009;2:153–62.
81. Ball SG, Desaiah D, Zhang Q, Thase ME, Perahia DG. Efficacy
and safety of duloxetine 60 mg once daily in major depressive
disorder: a review with expert commentary. Drugs Context.
2013;212245.
82. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA.
Duloxetine, 60 mg once daily, for major depressive disorder: a
randomized double-blind placebo-controlled trial. J Clin Psy-
chiatry. 2002;63:308–15.
83. Michel MC, Oelke M. Duloxetine in the treatment of stress
urinary incontinence. Womens Health (Lond). 2005;1:345–58.
84. Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt
CH, Wohlreich MM. Duloxetine versus escitalopram and pla-
cebo: an 8-month, double-blind trial in patients with major
depressive disorder. Curr Med Res Opin. 2007;23:1303–18.
85. Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, De Ronchi D.
Novel antidepressants and panic disorder: evidence beyond
current guidelines. Neuropsychobiol. 2010;63:1–7.
86. Smith HS, Bracken D, Smith JM. Pharmacotherapy for
fibromyalgia. Front Pharmacol. 2011;2:17.
87. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM.
Duloxetine added to oral nonsteroidal anti-inflammatory drugs
for treatment of knee pain due to osteoarthritis: results of a
randomized, double-blind, placebo-controlled trial. Curr Med
Res Opin. 2011;27:2361–72.
88. Guerdjikova AI, McElroy SL, Kotwal R, Welge JA, Nelson E,
Lake K. High-dose escitalopram in the treatment of binge-eating
disorder with obesity: a placebo-controlled monotherapy trial.
Hum Psychopharmacol. 2008;23:1–11.
89. Montgomery SA, Andersen HF. Escitalopram versus venlafax-
ine XR in the treatment of depression. Int Clin Psychopharma-
col. 2006;21:297–309.
90. Bhat A, El Solh AA. Management of narcolepsy. Exp Opin
Pharmacotherapy. 2008;9:1721–33.
91. Atkinson JH, Slater MA, Capparelli EV, Wallace MS, Zisook S,
Abranson I, et al. Efficacy of noradrenergic and serotonergic
antidepressants in chronic back pain: a preliminary concentra-
tion-controlled trial. J Clin Psychopharmacol. 2007;27:135–42.
92. Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J,
et al. Electrocardiographic effects of fluoxetine and doxepin in
patients with major depressive disorder. J Clin Psychopharma-
col. 1997;17:15–21.
93. Newhouse PA, Krishnan KRR, Doraiswamy PM, Richter EM,
Batzar ED, Clary CM. A double-blind comparison of sertraline
and fluoxetine in depressed elderly outpatients. J Clin Psychia-
try. 2000;61:559–68.
94. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R,
et al. Fluoxetine in the treatment of premenstrual dysphoria.
N Engl J Med. 1995;332:1529–34.
95. Kendirci M, Salem E, Hellstrom WJG. Dapoxetine, a novel
selective serotonin transport inhibitor for the treatment of pre-
mature ejaculation. Ther Clin Risk Manag. 2007;3:277–89.
96. Atkinson JC, Shiroky JB, Macynski A, Fox PC. Effects of fur-
osemide on the oral cavity. Gerodontology. 1989;8:23–6.
97. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden
RL. Nortriptyline and gabapentin, alone and in combination for
neuropathic pain: a double-blind, randomised controlled cross-
over trial. Lancet. 2009;374:1252–61.
Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia and Subjective Sialorrhea 23
98. Homma Y, Yamaguchi O. A randomized, double-blind, pla-
cebo- and propiverine-controlled trial of the novel antimus-
carinic agent imidafenacin in Japanese patients with overactive
bladder. Int J Urol. 2009;16:499–506.
99. Kasper S, Moller HJ, Montgomery SA, Zondag E. Antidepres-
sant efficacy in relation to item analysis and severity of
depression: a placebo-controlled trial of fluvoxamine versus
imipramine. Int Clin Psychopharmacol. 1995;9(Suppl 4):3–12.
100. Billiard M. Narcolepsy: current treatment options and future
approaches. Neuropsych Dis Treatment. 2008;4:557–66.
101. Brown TE, Brams M, Gao J, Gasior M, Childress A. Open-label
administration of lisdexamfetamine dimesylate improves exec-
utive function impairments and symptoms of attention-deficit/
hyperactivity disorder in adults. Postgrad Med. 2010;122:7–17.
102. Wigal T, Brams M, Gasior M, Gao J, Giblin J. Effect size of
lisdexamfetamine dimesylate in adults with attention-deficit/
hyperactivity disorder. Postgrad Med. 2011;123:169–75.
103. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones
M, et al. A randomized, double-blind, placebo-controlled effi-
cacy and safety study of quetiapine or lithium as monotherapy
for mania in bipolar disorder. J Clin Psychiatry.
2005;66:111–21.
104. O’Connell AC, Bowen WH. Composition and flow rate of saliva
and caries development in young rats following administration
of lithium. Caries Res. 1994;28:342–7.
105. Donaldson SR. Sialorrhea as a side effect of lithium: a case
report. Am J Psychiatry. 1982;138:1350–1.
106. Young AH, McElroy SL, Bauer M, Philips N, Chang W,
Olausson B, et al. A double-blind, placebo-controlled of queti-
apine and lithium monotherapy in adults in the acute phase of
bipolar depression (EMBOLDEN 1). J Clin Psychiatry.
2010;71:150–62.
107. Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar
P, et al. Efficacy and safety of loxapine for inhalation in the
treatment of agitation in patients with schizophrenia: a ran-
domized, double-blind, placebo-controlled trial. J Clin Psychiat.
2011;72:1313–21.
108. Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V.
Stimulant-responsive and stimulant-refractory aggressive
behavior among children with ADHD. Pediatrics.
2010;126:e796–806.
109. Devos D, Krystkowiak P, Clement F, Dujardin A, Cottencin O,
Waucquier N, et al. Improvement of gait by chronic, high doses
of methylphenidate in patients with advanced Parkinson’s dis-
ease. J Neurol Neurosurg Psychiatry. 2007;78:470–5.
110. Lasheen W, Walsh D, Mahmoud F, Davis MP, Rivera N,
Khoshknabi DS. Methylphenidate side effects in advanced
cancer: a retrospective analysis. Am J Hosp Palliat Care.
2010;27:16–23.
111. Biederman J, Mick E, Surman C, Doyle R, Hammerness P,
Harpold T, et al. A randomized, placebo-controlled trial of
OROS methylphenidate in adults with attention-deficit/hyper-
activity disorder. Biol Psychiatry. 2006;59:829–35.
112. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A per-
spective on their use in the elderly. Drugs Aging.
1998;13:341–55.
113. Johnsen E, Jorgensen HA. Effectiveness of second generation
antipsychotics: a systematic review of randomized trials. BMC
Psychiatry. 2008;8:1–14.
114. Kumar A, Gupta M, Jiloha RC, Tekur U. Efficacy of olanzapine
and sodium valproate given alone or as add-on therapy in acute
mania. A comparative study. Methods Find Exp Clin Pharmacol.
2010;32:319–24.
115. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides
J. Asenapine versus olanzapine in acute mania: a double-blind
extension study. Bipolar Disord. 2009;11:815–26.
116. Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M,
et al. A rapid and systematic review and economic evaluation of
the clinical and cost-effectiveness of newer drugs for treatment
of mania associated with bipolar affective disorder. Health
Technol Assess. 2004;8:iii–iv,1–187.
117. Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-
label study of the treatment efficacy of olanzapine for Tourette’s
disorder. J Clin Psychiatry. 2001;62:290–4.
118. Conley RR, Meltzer HY. Adverse events related to olanzapine.
J Clin Psychiatry. 2000;61:6–30.
119. Fulton B, Goa KL. Olanzapine. A review of its properties and
therapeutic efficacy in the management of schizophrenia and
related psychoses. Drugs. 1997;53:281–98.
120. Godoy T, Riva A, Ekstro¨m J. Salivary secretion effects of the
antipsychotic drug olanzapine in an animal model. Oral Dis.
2013;19:151–61.
121. Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker
S, Hoffmann VP, et al. Impact of race on efficacy and safety
during treatment with olanzapine in schizophrenia,
schizophreniform or schizoaffective disorder. BMC Psychiatry.
2010;10:89–99.
122. Barkin J, Corcos J, Radomski S, Jammal MP, Micelli PC, Reiz
JL. A randomized, double-blind, parallel-group comparison of
controlled- and immediate-release oxybutynin chloride in urge
urinary incontinence. Clin Therapeutics. 2004;26:1026–36.
123. Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of
patient and physician satisfaction with controlled-release oxy-
butynin 15 mg as a one-step daily dose in elderly and non-
elderly patients with overactive bladder: results of the STOP
study. Curr Med Res Opin. 2012;28:1369–79.
124. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and
tolerability of extended-release tolterodine and immediate-re-
lease oxybutynin in Japanese and Korean patients with an
overactive bladder: a randomized, placebo-controlled trial. BJU
Int. 2003;92:741–7.
125. Lucente VR, Staskin DR, De E. Development of oxybutynin
chloride topical gel for overactive bladder. Open Access J Urol.
2011;3:35–42.
126. Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR.
Effects of oxybutynin transdermal system on health-related
quality of life and safety in men with overactive bladder and
prostate conditions. Int J Clin Pract. 2008;62:27–38.
127. Madersbacher H, Halaska M, Voigt R, Alloussi S, Ho¨fner K. A
placebo-controlled, multicentre study comparing the tolerability
and efficacy of propiverine and oxybutynin in patients with
urgency and urge incontinence. BJU Int. 1999;84:646–51.
128. Garely AD, Burrows LJ. Current pharmacotherapeutic strategies
for overactive bladder. Exp Opin Pharmacother. 2002;3:827–33.
129. Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinergic
drugs versus placebo for overactive bladder syndrome in adults.
Cochrane Database Syst Rev. 2002;(3):CD003781.
130. Kay GG, Staskin DR, MacDiarmid S, McIlwain M, Dahl NV.
Cognitive effects of oxybutynin chloride topical gel in older
healthy subjects: a 1-week, randomized, double-blind, placebo-
and active-controlled study. Clin Drug Investig.
2012;32:707–14.
131. Lauti M, Herbison P, Hay-Smith J, Ellis G, Wilson D. Anti-
cholinergic drugs, bladder retraining and their combination for
urge urinary incontinence: a pilot randomised trial. Int Urogy-
necol J Pelvic Floor Dysfunct. 2008;19:1533–43.
132. MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski
RR. Efficacy and safety of extended release oxybutynin for the
treatment of urge incontinence: an analysis of data from 3
flexible dosing studies. J Urol. 2005;174(4 Pt 1):1301–5 (dis-
cussion 1305).
24 A. Wolff et al.
133. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anti-
cholinergic drugs versus placebo for overactive bladder syn-
drome in adults. Cochrane Database Syst Rev.
2006;(4):CD003781.
134. Hashim H, Abrams P. Drug treatment of overactive bladder:
efficacy, cost and quality-of-life considerations. Drugs.
2004;64:1643–56.
135. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating
smooth muscle contractility in the urinary bladder. Life Sci.
1999;64:419–28.
136. Michel MC. A benefit-risk assessment of extended-release
oxybutynin. Drug Saf. 2002;25:867–76.
137. Abrams P, Andersson KE. Muscarinic receptor antagonists for
overactive bladder. BJU Int. 2007;100:987–1006.
138. Naruganahalli KS, Sinha S, Hegde LG, Meru AV, Chugh A,
Kumar N, et al. Comparative in vivo uroselectivity profiles of
anticholinergics, tested in a novel anesthetized rabbit model. Eur
J Pharmacol. 2007;572:207–12.
139. Oki T, Takeuchi C, Yamada S. Comparative evaluation of
exocrine muscarinic receptor binding characteristics and inhi-
bition of salivation of solifenacin in mice. Biol Pharm Bull.
2006;29:1397–400.
140. Sakaguchi M, Goto K, Ichiki H, Hattori N, Iizuka A, Yamamoto
M, et al. Effects of Byakko-ka-ninjin-to on salivary secretion
and bladder function in rats. J Ethnopharmacol.
2005;102:164–9.
141. Sathyan G, Chancellor MB, Gupta SK. Effect of OROS con-
trolled-release delivery on the pharmacokinetics and pharma-
codynamics of oxybutynin chloride. Br J Clin Pharmacol.
2001;52:409–17.
142. Armstrong RB, Luber KM, Peters KM. Comparison of dry
mouth in women treated with extended-release formulations of
oxybutynin or tolterodine for overactive bladder. Int Urol
Nephrol. 2005;37:247–52.
143. Canuso CM, Turkoz I, Sheehan JJ, Bossie CA. Efficacy and
safety of paliperidone extended-release in schizophrenia patients
with prominent affective symptoms. J Affect Disord.
2010;120:193–9.
144. Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough
DW, et al. A randomized, placebo- and active-controlled study
of paliperidone extended release for the treatment of acute
manic and mixed episodes of bipolar I disorder. Bipolar Disord.
2010;12:230–43.
145. Kodish I, Rockhill C, Varley C. Pharmacotherapy for anxiety
disorders in children and adolescents. Dialogues Clin Neurosci.
2011;13:439–52.
146. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B,
Schwiers ML, et al. Effects of low-dose, controlled-release,
phentermine plus topiramate combination on weight and asso-
ciated comorbidities in overweight and obese adults (CON-
QUER): a randomised, placebo-controlled, phase 3 trial. Lancet.
2011;377:1341–52.
147. Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on
weight reduction and safety of short-term phentermine admin-
istration in Korean obese people. Yonsei Med J.
2006;47:614–25.
148. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers
ML, Najarian T, et al. Controlled-release phentermine/topira-
mate in severely obese adults: a randomized controlled trial
(EQUIP). Obesity (Silver Spring). 2012;20:330–42.
149. Scheepe JR, Braun PM, Junemann KP, Alken P. Effects of
propiverine and its metabolite propiverine-N-oxide on bladder
contraction and salivation in mini pigs. Urol Int.
2008;81:468–73.
150. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astro¨m M,
Brecher M. Extended release quetiapine fumarate monotherapy
in major depressive disorder: a placebo- and duloxetine-con-
trolled study. J Clin Psychiatry. 2009;70:526–39.
151. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C,
Lindgren P, et al. Extended-release quetiapine fumarate (queti-
apine XR) as adjunctive therapy in major depressive disorder
(MDD) in patients with an inadequate response to ongoing
antidepressant treatment: a multicentre, randomized, double-
blind, placebo-controlled study. Int J Neuropsychopharmacol.
2010;13:917–32.
152. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C,
Darko D. Effectiveness of the extended release formulation of
quetiapine as monotherapy for the treatment of acute bipolar
depression. J Affect Disord. 2010;121:106–15.
153. Timdahl K, Carlsson A, Stening G. An analysis of safety and
tolerability data from controlled, comparative studies of queti-
apine in patients with schizophrenia, focusing on extrapyramidal
symptoms. Hum Psychopharmacol. 2007;22:315–25.
154. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus
A. Efficacy of extended release quetiapine fumarate monother-
apy in patients with major depressive disorder: a pooled analysis
of two 6-week, double-blind, placebo-controlled studies. Int
Clin Psychopharmacol. 2012;27:27–39.
155. Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S.
Efficacy and safety of quetiapine in adolescents with
schizophrenia investigated in a 6-week, double-blind, placebo-
controlled trial. J Child Adolescent Psychopharmacol.
2012;22:327–42.
156. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and toler-
ability of extended release quetiapine fumarate monotherapy in
the acute treatment of generalized anxiety disorder: a random-
ized, placebo controlled and active-controlled study. Int Clin
Psychopharmacol. 2012;27:40–54.
157. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu
G, De Sarro G. Adverse effects of atypical antipsychotics in the
elderly: a review. Drugs Aging. 2006;23:937–56.
158. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu
S, Eriksson H. Extended release quetiapine fumarate (quetiapine
XR) monotherapy as maintenance treatment for generalized
anxiety disorder: a long-term, randomized, placebo-controlled
trial. Int Clin Psychopharmacol. 2011;26:11–24.
159. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J,
Brecher M. Extended-release quetiapine as adjunct to an
antidepressant in patients with major depressive disorder: results
of a randomized, placebo-controlled, double-blind study. J Clin
Psychiatry. 2009;70:540–9.
160. Schatzberg AF. Clinical efficacy of reboxetine in major
depression. J Clin Psychiatry. 2000;61(Suppl 10):31–8.
161. Versiani M, Amin M, Chouinard G. Double-blind, placebo-
controlled study with reboxetine in inpatients with severe major
depressive disorder. J Clin Psychopharmacol. 2000;20:28–34.
162. Lo´pez-Mun˜oz F, Rubio G, Alamo C, Garcia-Garcia P. Rebox-
etine addition in patients with mirtazapine-resistant depression:
a case series. Clin Neuropharmacol. 2006;29:192–6.
163. Riahi F, Tehrani-Doost M, Shahrivar Z, Alaghband-Rad J.
Efficacy of reboxetine in adults with attention-deficit/hyperac-
tivity disorder: a randomized, placebo-controlled clinical trial.
Hum Psychopharmacol. 2010;25:570–6.
164. Malone RP, Gratz SS, Delaney MA, Hyman SB. Advances in
drug treatments for children and adolescents with autism and
other pervasive developmental disorders. CNS Drugs.
2005;19:923–34.
165. Wu A, Wagner ML. Rotigotine transdermal system for the
treatment of restless legs syndrome. Future Neurol.
2009;4:267–77.
166. Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW,
Becker P, et al. Rotigotine improves restless legs syndrome: a
Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia and Subjective Sialorrhea 25
6-month randomized, double-blind, placebo-controlled trial in
the United States. Mov Disord. 2010;25:1675–83.
167. Finlay E, Straton JB, Gavrin JR. Nausea and vomiting: an
overview of mechanisms and treatment in older patients. Geriatr
Aging. 2007;10:116–21.
168. Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi
SH, Tabrizi M, et al. Oral scopolamine augmentation in mod-
erate to severe major depressive disorder: a randomized, double-
blind, placebo-controlled study. J Clin Psychiatry.
2012;73:1428–33.
169. Kaya A, Aydin N, Topsever P, Filiz M, Oztu¨rk A, Dag˘ar A,
et al. Efficacy of sibutramine, orlistat and combination therapy
on short-term weight management in obese patients. Biomed
Pharmacother. 2004;58:582–7.
170. Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI,
Blakesley V, et al. Efficacy of sibutramine for the treatment of
binge eating disorder: a randomized multicenter placebo-con-
trolled double-blind study. Am J Psychiatry. 2008;165:51–8.
171. But I, Goldstajn MS, Oreskovic S. Comparison of two selective
muscarinic receptor antagonists (solifenacin and darifenacin) in
women with overactive bladder–the SOLIDAR study. Coll
Antropol. 2012;36:1347–53.
172. Chancellor MB, Zinner N, Whitmore K, Kobayashi K, Snyder
JA, Siami P. et al. Efficacy of solifenacin in patients previously
treated with tolterodine extended release 4 mg: results of a
12-week, multicenter, open-label, flexible-dose study. Clin Ther.
2008;30:1766–81.
173. Chu F, Smith N, Uchida T. Efficacy and safety of solifenacin
succinate 10 mg once daily: a multicenter, phase III, random-
ized, double-blind, placebo-controlled, parallel-group trial in
patients with overactive bladder. Curr Therap Res Clin Exp.
2009;70:405–20.
174. Mattiasson A, Masala A, Morton R, Bolodeoku J. Efficacy of
simplified bladder training in patients with overactive bladder
receiving a solifenacin flexible-dose regimen: Results from a
randomized study. BJU Int. 2010;105:1126–35.
175. Serels SR, Toglia MR, Forero-Schwanhaeuser S, He W. Impact
of solifenacin on diary-recorded and patient-reported urgency in
patients with severe overactive bladder (OAB) symptoms. Curr
Med Res Opin. 2010;26:2277–85.
176. Metello J, Nogueira B, Torgal M, Colac¸o J, Vieira A, Gonc¸alves
V, et al. Comparison of the efficacy and tolerability of solife-
nacin succinate with or without previous use of trospium chlo-
ride. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1021–5.
177. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP,
Larsen TM. Effect of tesofensine on bodyweight loss, body
composition, and quality of life in obese patients: a randomised,
double-blind, placebo-controlled trial. Lancet.
2008;372:1906–13.
178. Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk
benefit analysis of tiotropium in COPD. Int J Chron Obstruct
Pulmon Dis. 2008;3:575–84.
179. Kerstjens HAM, Disse B, Schroder-Babo W, Bantje TA,
Gahlemann M, Sigmund R, et al. Tiotropium improves lung
function in patients with severe uncontrolled asthma: a ran-
domized controlled trial. J Allergy Clin Immunol.
2011;128:308–14.
180. Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety
of tolterodine extended release and dutasteride in male overac-
tive bladder patients with prostates [30 grams. Urology.
2010;75:1144–8.
181. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brod-
sky M, et al. Comparison of fesoterodine and tolterodine
extended release for the treatment of overactive bladder: a head-
to-head placebo-controlled trial. BJU Int. 2010;105:58–66.
182. Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy
and safety of two doses of tolterodine versus placebo in patients
with detrusor overactivity and symptoms of frequency, urge
incontinence, and urgency: urodynamic evaluation. The Inter-
national Study Group. World J Urol. 1997;15:144–51.
183. McKeage K, Keating GM. Fesoterodine. Drugs. 2009;69:731–8.
184. Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T,
Guan Z, et al. Efficacy and tolerability of tolterodine extended-
release in continent patients with overactive bladder and noc-
turia. BJU Int. 2006;97:1262–6.
185. Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S,
Guan Z. Efficacy and tolerability of tolterodine extended-release
in men with overactive bladder and urgency urinary inconti-
nence. BJU Int. 2006;97:1003–6.
186. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and
tolerability of extended-release once-daily tolterodine treatment
for overactive bladder in older versus younger patients. J Am
Geriatr Soc. 2002;50:799–807.
187. Griebling TL, Kraus SR, Richter HE, Glasser DB, Carlsson M.
Tolterodine extended release is well tolerated in older subjects.
Int J Clin Pract. 2009;63:1198–204.
188. Sacco E, Bientinesi R. Mirabegron: a review of recent data and
its prospects in the management of overactive bladder. Ther Adv
Urol. 2012;4:315–24.
189. Speciali JG, Stuginski-Barbosa J. Burning mouth syndrome.
Curr Pain Headache Rep. 2008;12:279–84.
190. Maruyama I, Yonekubo S, Tatemichi S, Maruyama K, Hoyano
Y, Yamazaki Y, et al. Effects of ritobegron (KUC-7483), a novel
beta3-adrenoceptor agonist, on both rat bladder function fol-
lowing partial bladder outlet obstruction and on rat salivary
secretion: a comparison with the effects of tolterodine. J Smooth
Muscle Res. 2012;48:115–24.
191. Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K,
Milsom I, et al. Efficacy and tolerability of mirabegron, a beta3-
adrenoceptor agonist, in patients with overactive bladder:
Results from a randomised European-Australian phase 3 trial.
Eur Urol. 2013;63:283–95.
192. Barton D, La Vasseur B, Loprinzi C, Novotny P, Wilwerding
MP, Sloan J. Venlafaxine for the control of hot flashes: results of
a longitudinal continuation study. Oncol Nurs Forum.
2002;29:33–40.
193. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-
daily venlafaxine extended release (XR) for symptoms of anx-
iety in depressed outpatients. J Affect Disord. 1998;47:55–62.
194. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT,
Salinas E. Efficacy of venlafaxine extended-release capsules in
nondepressed outpatients with generalized anxiety disorder: a
6-month randomized controlled trial. JAMA. 2000;283:3082–8.
195. Staab JP, Evans DL. Efficacy of venlafaxine in geriatric
depression. Depress Anxiety. 2000;12(Suppl 1):63–8.
196. Krevsky B, Maurer AH, Niewiarowski T, Cohen S. Effect of ver-
apamil on human intestinal transit. Dig Dis Sci. 1992;37:919–24.
197. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M,
Sheehan DV. Vortioxetine (Lu AA21004) 5 mg in generalized
anxiety disorder: Results of an 8-week randomized, double-
blind, placebo-controlled clinical trial in the United States. Eur
Neuropsychopharmacol. 2012;22:858–66.
198. Harrington CA, English C. Adverse drug events related to
ziprasidone: a meta-analysis of randomized, placebo-controlled
trials. Pharmacotherapy. 2011;31:840–9.
199. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka
JM, Kinrys G, et al. A 12-week, randomized, double-blind,
placebo-controlled, sequential parallel comparison trial of
ziprasidone as monotherapy for major depressive disorder.
J Clin Psychiatry. 2012;73:1541–7.
26 A. Wolff et al.
200. Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B,
Sheehan DV, et al. Improved insomnia symptoms and sleep-
related next-day functioning in patients with comorbid major
depressive disorder and insomnia following concomitant zolpi-
dem extended-release 12.5 mg and escitalopram treatment: a
randomized controlled trial. J Clin Psychiatry. 2011;72:914–28.
201. Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P,
Winer E, et al. Augmentation of venlafaxine and selective
serotonin reuptake inhibitors with zolpidem improves sleep and
quality of life in breast cancer patients with hot flashes: a ran-
domized, double-blind, placebo-controlled trial. Menopause.
2010;17:908–16.
202. Brunton LL. Goodman & Gilman’s the pharmacological basis of
therapeutics. 12th ed. New York: McGraw-Hill Medical; 2011.
203. Godoy T, Riva A, Ekstro¨m J. Atypical antipsychotics—effects
of amisulpride on salivary secretion and on clozapine-induced
sialorrhea. Oral Dis. 2012;18:680–91.
204. Timpe EM, Chopra RA. Asenapine: a novel atypical antipsy-
chotic agent for schizophrenia and bipolar I disorder. J Phar-
macy Technol. 2010;26:352–61.
205. Croog SH, Elias MF, Colton T, Baume RM, Leiblum SR,
Jenkins CD. Effects of antihypertensive medications on quality
of life in elderly hypertensive women. Am J Hypertens.
1994;7:329–39.
206. Henz BM, Metzenauer P, O’Keefe E, Zuberbier T. Differential
effects of new-generation H1-receptor antagonists in pruritic
dermatoses. Allergy. 1998;53:180–3.
207. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs.
2001;61:2231–2240 (discussion 2241–2232).
208. Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, et al.
Impact of CYP2C19 polymorphisms on efficacy of clobazam
therapy. Pharmacogenomics. 2008;9:527–37.
209. Koller MM, Cowman RA, Humphreys-Beher MG, Scarpace PJ.
An analysis of parotid salivary gland function with desipramine
and age in female NIA Fischer 344 rats. Exp Gerontol.
2001;36:141–57.
210. Aberer W. Desloratadine for the relief of nasal and non-nasal
allergy symptoms: an observational study. Arch Drug Inf.
2009;2:17–22.
211. Wilken JA, Daly AF, Sullivan CL, Kim H. Desloratadine for
allergic rhinitis. Exp Rev Clin Immunol. 2006;2:209–24.
212. Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK,
Guico-Pabia CJ. Analysis by age and sex of efficacy data from
placebo-controlled trials of desvenlafaxine in outpatients with
major depressive disorder. J Clin Psychopharmacol.
2010;30:294–9.
213. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R,
Tummala R, Tourian KA. Efficacy, safety, and tolerability of
desvenlafaxine 50 mg/day and 100 mg/day in outpatients with
major depressive disorder. Curr Med Res Opin.
2008;24:1877–90.
214. Pae CU. Desvenlafaxine: a new antidepressant or just another
one? Exp Opin Pharmacotherapy. 2009;10:875–87.
215. Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR. A
10-month, open-label evaluation of desvenlafaxine in outpa-
tients with major depressive disorder. Prim Care Companion
CNS Disord. 2011;13:e1–10.
216. Swinburn BA, Carmichael HE, Wilson MR. Dexfenfluramine as
an adjunct to a reduced-fat, ad libitum diet: effects on body
composition, nutrient intake and cardiovascular risk factors. Int
J Obes Relat Metab Disord. 1996;20:1033–40.
217. Davis R, Faulds D. Dexfenfluramine. An updated review of its
therapeutic use in the management of obesity. Drugs.
1996;52:696–724.
218. Bajwa SJ, Arora V, Kaur J, Singh A, Parmar SS. Comparative
evaluation of dexmedetomidine and fentanyl for epidural
analgesia in lower limb orthopedic surgeries. Saudi J Anaesth.
2011;5:365–70.
219. Diz Dios P, Scully C. Antiretroviral therapy: effects on orofacial
health and health care. Oral Dis. 2014;20:136–45.
220. Freye E, Baranowski J, Latasch L. Dose-related effects of
controlled release dihydrocodeine on oro-cecal transit and
pupillary light reflex. A study in human volunteers. Arzneimit-
telforschung. 2001;51:60–6.
221. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse
drug reactions in hospital in-patients: a pilot study. J Clin Pharm
Therap. 2006;31:335–41.
222. Kalis B. Double-blind multicentre comparative study of ebas-
tine, terfenadine and placebo in the treatment of chronic idio-
pathic urticaria in adults. Drugs. 1996;52(Suppl 1):30–4.
223. Storms WW. Clinical studies of the efficacy and tolerability of
ebastine 10 or 20 mg once daily in the treatment of seasonal
allergic rhinitis in the US. Drugs. 1996;52(Suppl 1):20–5.
224. Pelaez A. Clinical efficacy of ebastine in the treatment and pre-
vention of seasonal allergic rhinitis. Drugs. 1996;52(Suppl 1):35–8.
225. Halas CJ. Cost-effectiveness of eszopiclone for the treatment of
chronic insomnia. Expert Rev Pharmacoecon Outcomes Res.
2007;7:9–17.
226. Monti JM, Pandi-Perumal SR. Eszopiclone: Its use in the treat-
ment of insomnia. Neuropsychiatr Dis Treat. 2007;3:441–53.
227. Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer
K, et al. Eszopiclone coadministered with escitalopram in
patients with insomnia and comorbid generalized anxiety dis-
order. Arch Gen Psychiatry. 2008;65:551–62.
228. Tzefos M, Dolder C, Olin JL. Fesoterodine for the treatment of
overactive bladder. Ann Pharmacotherapy. 2009;43:1992–2000.
229. Kay GG, Maruff P, Scholfield D, Malhotra B, Whelan L, Dar-
ekar A. Evaluation of cognitive function in healthy older sub-
jects treated with fesoterodine. Postgrad Med. 2012;124:7–15.
230. Yamaguchi O, Nishizawa O, Takeda M, Yoshida M, Choo MS,
Gu Lee J, et al. Efficacy, safety and tolerability of fesoterodine
in Asian patients with overactive bladder. Low Urin Tract
Symptoms. 2011;3:43–50.
231. Bova JG, Jurdi RA, Bennett WF. Antispasmodic drugs to reduce
discomfort and colonic spasm during barium enemas: compar-
ison of oral hyoscyamine, i.v. glucagon, and no drug. AJR Am J
Roentgenol. 1993;161:965–8.
232. Fang SY, Perng DW, Lee JY, Lin DY, Huangs CY. An open-
label, multicentre study of levocetirizine for the treatment of
allergic rhinitis and urticaria in Taiwanese patients. Chin J
Physiol. 2010;53:199–207.
233. Gerc V, Begovic´ B, Vehabovic´ M, Voronkov LG, Vataman E,
Music´ L, et al. Fixed combination lisinopril plus hydro-
chlorothiazide in the treatment of essential arterial hypertension:
an opened, multi-centre, prospective clinical trial. Bosn J Basic
Med Sci. 2007;7:377–82.
234. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J,
Pikalov A, et al. Effectiveness of lurasidone in patients with
schizophrenia or schizoaffective disorder switched from other
antipsychotics: a randomized, 6-week, open-label study. J Clin
Psychiatry. 2013;74:170–9.
235. Aneja P, Srinivas A, Biswas AD. Comparative clinical study of
the efficacy and safety of a S-metoprolol ER tablet versus a
racemate metoprolol ER tablet in patients with chronic
stable angina. Int J Clin Pharmacol Ther. 2007;45:253–8.
236. Momo K, Homma M, Osaka Y, Inomata S, Tanaka M, Kohda Y.
Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine phar-
macokinetics and pharmacodynamics. J Clin Pharmacol.
2010;50:331–7.
237. Vickers MD, Paravicini D. Comparison of tramadol with mor-
phine for post-operative pain following abdominal surgery. Eur
J Anaesthesiol. 1995;12:265–71.
Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia and Subjective Sialorrhea 27
238. Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson
WK. A dose-response analysis of the subjective, psychomotor
and physiological effects of intravenous morphine in healthy
volunteers. J Pharmacol Exp Ther. 1994;268:1–9.
239. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind nal-
trexone and placebo comparison study in the treatment of
pathological gambling. Biol Psychiatry. 2001;49:914–21.
240. Ossip DJ, Abrams SM, Mahoney MC, Sall D, Cummings KM.
Adverse effects with use of nicotine replacement therapy among
quitline clients. Nicotine Tob Res. 2009;11:408–17.
241. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D,
Russo C. Effect of an electronic nicotine delivery device (e-
Cigarette) on smoking reduction and cessation: a prospective
6-month pilot study. BMC Public Health. 2011;11:786.
242. Bull E. Drug review - Pregabalin. Drugs. Context. 2006;2:65–77.
243. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation
of the safety and efficacy of pregabalin in older patients with
neuropathic pain: results from a pooled analysis of 11 clinical
studies. BMC Fam Pract. 2010;11:85.
244. Vinik A. Clinical review: use of antiepileptic drugs in the
treatment of chronic painful diabetic neuropathy. J Clin Endo-
crinol Metab. 2005;90:4936–45.
245. Murdoch D, Keating GM. Sertindole: a review of its use in
schizophrenia. CNS Drugs. 2006;20:233–55.
246. Karamatskos E, Lambert M, Mulert C, Naber D. Drug safety and
efficacy evaluation of sertindole for schizophrenia. Expert Opin
Drug Saf. 2012;11:1047–62.
247. Steigerwald I, Muller M, Davies A, Samper D, Sabatowski R,
Baron R, et al. Effectiveness and safety of tapentadol prolonged
release for severe, chronic low back pain with or without a
neuropathic pain component: Results of an open-label, phase 3b
study. Curr Med Res Opin. 2012;28:911–36.
248. Lee E, Lee C. Clinical comparison of selective and non-selective
alpha 1A-adrenoreceptor antagonists in benign prostatic hyper-
plasia: studies on tamsulosin in a fixed dose and terazosin in
increasing doses. Br J Urol. 1997;80:606–11.
249. Semenchuk MR, Sherman S. Effectiveness of tizanidine in
neuropathic pain: an open-label study. J Pain. 2000;1:285–92.
250. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS,
et al. Efficacy and safety of oral tolvaptan therapy in patients
with the syndrome of inappropriate antidiuretic hormone
secretion. Eur J Endocrinol. 2011;164:725–32.
251. Delahaye C, Ferrand B, Pieddeloup C, Musch B. Post marketing
surveillance of zopiclone: interim analysis on the first 10,000
cases in a clinical study in general practice. Int Clin Psy-
chopharmacol. 1990;5(Suppl 2):131–8.
252. Mangel AW, Hicks GA. Asimadoline and its potential for the
treatment of diarrhea-predominant irritable bowel syndrome: a
review. Clin Exp Gastroenterol. 2012;5:1–10.
253. Simpson D, Plosker GL. Atomoxetine: a review of its use in
adults with attention deficit hyperactivity disorder. Drugs.
2004;64:205–22.
254. Bouwer A. Combination cold and flu medicines: an overview of
autonomic nervous system receptors. S Afr Fam Pract.
2012;54:33–6.
255. Boven E, Westerman M, van Groeningen CJ, Verschraagen M,
Ruijter R, et al. Phase I and pharmacokinetic study of the novel
chemoprotector BNP7787 in combination with cisplatin and
attempt to eliminate the hydration schedule. Br J Cancer.
2005;92:1636–43.
256. Tutka P, Zatonski W. Cytisine for the treatment of nicotine
addiction: From a molecule to therapeutic efficacy. Pharmacol
Rep. 2006;58:777–98.
257. Friedel HA, Fitton A. Flupirtine. A review of its pharmacolog-
ical properties, and therapeutic efficacy in pain states. Drugs.
1993;45:548–69.
258. Moreno J, Sahade M, del Giglio A. Low-dose granisetron for
prophylaxis of acute chemotherapy-induced nausea and vomit-
ing: a pilot study. Support Care Cancer. 2005;13:850–3.
259. Vongpatanasin W, Kario K, Atlas SA, Victor RG. Central
sympatholytic drugs. J Clin Hypertens (Greenwich).
2011;13:658–61.
260. Newnham DM. Asthma medications and their potential adverse
effects in the elderly: recommendations for prescribing. Drug
Saf. 2001;24:1065–80.
261. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS.
Milnacipran for the management of fibromyalgia syndrome.
J Pain Res. 2010;3:15–24.
262. Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A,
Heldt E. et al. The efficacy of milnacipran in panic disorder: An
open trial. Int Clin Psychopharmacol. 2007;22:153–8.
263. Coskun M, Ahmetoglu E, Ozturk M. Mirtazapine treatment for
comorbid anxiety/depressive disorders in young subjects with
attention-deficit hyperactivity disorder: case series. Klinik
Psikofarmakoloji Bulteni. 2010;20:246–51.
264. Schwartz JRL. Modafinil in the treatment of excessive sleepi-
ness. Drug Des Dev Ther. 2008;2:71–85.
265. Curran MP, Robinson DM. Mosapride in gastrointestinal dis-
orders. Drugs. 2008;68:981–91.
266. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an
analysis of 14 years of clinical data. Drugs R D.
2012;12:71–100.
267. Prichard BN, Graham BR. I1 imidazoline agonists. General
clinical pharmacology of imidazoline receptors: implications for
the treatment of the elderly. Drugs Aging. 2000;17:133–59.
268. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am
J Health Syst Pharm. 1995;52:2799–812.
269. Davis R, Whittington R, Bryson HM. Nefazodone. A review of
its pharmacology and clinical efficacy in the management of
major depression. Drugs. 1997;53:608–36.
270. West D, Chambers S. Drug review—Perindopril. Drugs Context.
2006;2:17–34.
271. Wilde MI, Benfield P. Tianeptine—a review of its pharmaco-
dynamic and pharmacokinetic properties, and therapeutic effi-
cacy in depression and coexisting anxiety and depression.
Drugs. 1995;49:411–39.
272. Dawes C, Pedersen AM, Villa A, Ekstro¨m J, Proctor GB, Vis-
sink A, et al. The functions of human saliva: a review sponsored
by the World Workshop on Oral Medicine VI. Arch Oral Biol.
2015;60:863–74.
273. Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge
Pedersen AM, et al. World Workshop on Oral Medicine VI: a
systematic review of medication-induced salivary gland dys-
function. Oral Dis. 2016;22:365–82.
274. Aliko A, Wolff A, Dawes C, Aframian D, Proctor G, Ekstro¨m J,
et al. World Workshop on Oral Medicine VI: clinical implica-
tions of medication-induced salivary gland dysfunction. Oral
Surg Oral Med Oral Pathol Oral Radiol. 2015;120:185–206.
275. Villa A, Wolff A, Aframian D, Vissink A, Ekstro¨m J, Proctor G,
et al. World Workshop on Oral Medicine VI: a systematic
review of medication-induced salivary gland dysfunction:
prevalence, diagnosis, and treatment. Clin Oral Investig.
2015;19:1563–80.
276. WHO Collaborating Centre for Drug Statistics Methodology.
ATC/DDD Index. http://www.whocc.no/atc_ddd_index/?code=
A08AA&showdescription=yes. Accessed 9 Nov 2016.
277. WHO Collaborating Centre for Drug Statistics Methodology.
ATC/DDD Index 2016. http://www.whocc.no/atc_ddd_index/.
Accessed 9 Nov 2016.
28 A. Wolff et al.
